Physician profile
Michael A Samuels
NPI 1164890521
$12,740.13
in general payments reported to CMS, 2019-2025
27 companies · $3,083 in 2025
The $3,083 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,820 · 2020: $4,645 · 2021: $395 · 2022: $647 · 2023: $329 · 2024: $820 · 2025: $3,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,219 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Entertainment: $13.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,218.74 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Entertainment | $13.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,944.97 | 2019-2025 | Precision 1, Dailies Total1, Opti-Free Puremoist |
| Sight Sciences, INC. | $1,419.56 | 2020 | |
| Shire North American Group INC | $1,271.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $982.78 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $631.59 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Harrow Eye, LLC | $469.27 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $405.40 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $293.36 | 2020-2025 | Cequa |
| Dompe US, INC. | $290.17 | 2019-2025 | Oxervate |
| Coopervision INC. | $161.85 | 2019-2025 | Misight Contact Lens, Onefit Contact Lens |
| Oyster Point Pharma, INC. | $148.64 | 2022-2024 | Ryzumvi, Tyrvaya |
| Abb Con-Cise Optical Group LLC | $142.99 | 2019-2020 | |
| Biotissue Holdings INC. | $130.05 | 2019-2024 | |
| Abbvie INC. | $65.10 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $45.08 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $43.71 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $40.67 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $39.23 | 2022-2024 | |
| Thea Pharma INC. | $36.37 | 2023 | |
| Glaukos Corporation | $33.50 | 2019-2021 | |
| Amgen INC. | $32.94 | 2024-2025 | Tepezza |
| Ocular Therapeutix, INC. | $31.37 | 2021 | |
| Visioneering Technologies, INC. | $28.59 | 2019 | |
| Rxsight INC | $22.51 | 2022 | |
| Eyevance Pharmaceuticals LLC | $15.68 | 2021 | |
| Optos, INC. | $13.41 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Samuels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.